RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oramed Pharmaceuticals Stock

Oramed Pharmaceuticals ROCE 2024

Oramed Pharmaceuticals ROCE

-0.1

Ticker

ORMP

ISIN

US68403P2039

WKN

A1CTNU

In 2024, Oramed Pharmaceuticals's return on capital employed (ROCE) was -0.1, a -64.01% increase from the -0.27 ROCE in the previous year.

Oramed Pharmaceuticals Aktienanalyse

What does Oramed Pharmaceuticals do?

Oramed Pharmaceuticals Inc is an innovative biotech company headquartered in Jerusalem, Israel. The company was founded in 2006 by Nadav Kidron and specializes in the development of oral forms of protein-based therapeutics. The idea behind Oramed Pharmaceuticals was to revolutionize the way proteins are administered. Typically, protein-based drugs like insulin need to be administered in injectable form, which can be unpleasant and painful for many patients. Oramed Pharmaceuticals set out to find a solution to this problem. The company has developed a technology called ORMD-0801, which allows for the oral administration of insulin. The active ingredient is protected by a special capsule that monitors the pH level in the stomach. Once the capsule reaches the small intestine, the active ingredient is released and can be absorbed by the body. Oramed Pharmaceuticals aims to improve the treatment of diabetes. With the oral form of insulin, patients can take their medication much easier and more conveniently. This can help improve treatment and increase patients' quality of life. In addition to the development of ORMD-0801, Oramed Pharmaceuticals is also working on developing oral forms of other protein-based therapeutics. The company has filed a variety of patents for technologies and therapies and actively collaborates with other companies and research institutions. Oramed Pharmaceuticals has two main divisions: the development department and the commercialization department. The development department is responsible for the research and development of new therapies, while the commercialization department is responsible for sales and marketing of the products. Oramed Pharmaceuticals' business model is focused on developing innovative therapies and bringing them to market. The company works closely with other companies and research institutions to advance the development of new therapies. Oramed Pharmaceuticals is currently working on several projects to develop additional orally administered protein-based therapeutics. In addition to insulin, the company is also working on proteins that can be used in the treatment of other diseases such as osteoporosis and Parkinson's. The products of Oramed Pharmaceuticals are of great importance to both patients and the medical community. The oral forms of protein-based therapeutics can help make the treatment of diabetes and other diseases much easier and more convenient. This can help increase patient satisfaction and improve compliance. In recent years, Oramed Pharmaceuticals has received several awards and accolades for its innovative products. The company continues to work on developing new therapies and changing the way medication is administered. Oramed Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Oramed Pharmaceuticals's Return on Capital Employed (ROCE)

Oramed Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Oramed Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Oramed Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Oramed Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Oramed Pharmaceuticals stock

What is the ROCE (Return on Capital Employed) of Oramed Pharmaceuticals this year?

The ROCE of Oramed Pharmaceuticals is -0.1 undefined this year.

How has the ROCE (Return on Capital Employed) of Oramed Pharmaceuticals developed compared to the previous year?

The ROCE of Oramed Pharmaceuticals has increased by -64.01% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Oramed Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Oramed Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Oramed Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Oramed Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Oramed Pharmaceuticals impact the company?

An increase in the ROCE of Oramed Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Oramed Pharmaceuticals affect the company?

A decrease in ROCE of Oramed Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Oramed Pharmaceuticals?

Some factors that can affect Oramed Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Oramed Pharmaceuticals so important for investors?

The ROCE of Oramed Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Oramed Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Oramed Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Oramed Pharmaceuticals pay?

Over the past 12 months, Oramed Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oramed Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Oramed Pharmaceuticals?

The current dividend yield of Oramed Pharmaceuticals is .

When does Oramed Pharmaceuticals pay dividends?

Oramed Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oramed Pharmaceuticals?

Oramed Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Oramed Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oramed Pharmaceuticals located?

Oramed Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oramed Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oramed Pharmaceuticals from 9/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/11/2024.

When did Oramed Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/11/2024.

What was the dividend of Oramed Pharmaceuticals in the year 2023?

In the year 2023, Oramed Pharmaceuticals distributed 0 USD as dividends.

In which currency does Oramed Pharmaceuticals pay out the dividend?

The dividends of Oramed Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oramed Pharmaceuticals

Our stock analysis for Oramed Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oramed Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.